British Columbia-based Hytn Innovations is teaming up with 4C Labs, a Canadian cannabis distribution and product-development company, to produce medical marijuana for distribution in the United Kingdom and, potentially, other global markets.
The partnership allows cannabinoid-focused pharmaceutical company Hytn to manufacture, package and export pharmaceutical-quality cannabis products in bulk and packaged formats for 4C Labs to distribute in the UK, according to a news release.
Hytn holds a Good Manufacturing Practice (GMP) license from Health Canada as well as a PIC/S (Pharmaceutical Inspection Co-operation Scheme) certification from Australia’s Therapeutic Goods Administration, the release noted.
“This partnership validates the ongoing regulatory work Hytn has been undertaking,” Hytn CEO Elliot McKerr said in a prepared statement.
“By integrating 4C Labs’ deep understanding of cannabis procurement and consumer demand with our advanced GMP-certified manufacturing processes, we are well-positioned to deliver high-quality cannabis products to international markets.”
4C Labs CEO Greg Dobbin said the partnership will give his company a competitive advantage because of Hytn’s access to high-quality Canadian flower and its adherence to GMP standards.
While the partnership’s initial focus is to supply cannabis products to the U.K., the companies also are considering expansion opportunities in Australia and Germany.
The German medical cannabis market has an estimated value of $1.5 billion, according to Hytn, while the Australian market was valued at more than $1.3 million in 2022.
Both markets require GMP-certified production and distribution.
Last year, 4C Labs entered a supply agreement with Canada-based Organigram Holdings to provide dried medical marijuana flower for the U.K. market.
